Podcast: Elacestrant Seems Effective for HR-Resistant BC
Experimental Elacestrant Seems Effective for Breast Cancer Resistant to Other Types of Hormonal Therapy
Dec 8, 2022
Dr. Virginia Kaklamani explains the latest results from the EMERALD trial comparing elacestrant to the standard of care.
Doctors are looking for new treatment options for people diagnosed with metastatic hormone receptor-positive, HER2-negative breast cancer that has grown during treatment with hormonal therapy and a CDK4/6 inhibitor. Dr. Virginia Kaklamani is part of the team investigating elacestrant, an oral medicine, to see if offers more benefits than Faslodex (chemical name: fulvestrant), which is the current standard of care.
Listen to the podcast to hear Dr. Kaklamani explain:
- the type of medicine elacestrant is and how it works
- why it's important that elacestrant showed benefits for breast cancers with an ESR1 mutation
- when we might hear if elacestrant is approved by the U.S. Food and Drug Administration (FDA)